Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
Year: 2022
Type: article
Abstract: BACKGROUND: In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib. METHODS: We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety. RESULTS: Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib. CONCLUSIONS: Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.
Source: The Oncologist
Institutions: City Of Hope National Medical Center, City of Hope, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, Texas A&M University, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, University of Bari Aldo Moro, Fondazione IRCCS Istituto Nazionale dei Tumori, Georgetown Lombardi Comprehensive Cancer Center, AVEO Oncology (United States), Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,494
OpenAlex ID: W4313205689